Whole exome sequencing predicts immunotherapy response
2022
New York Genome Center, New York, USA
Immune checkpoint blockade (ICB) has transformed the treatment of metastatic cancer but is hindered by variable response rates. A key unmet need is the identification of biomarkers that predict treatment response. To address this, the researchers analysed six whole exome sequencing cohorts with matched disease outcomes to identify genes and pathways predictive of ICB response. Using this technique, they identify several genes (BCLAF1, KRAS, BRAF, and TP53) and pathways (MAPK signalling, p53 associated, and immunomodulatory) as predictors of ICB response and develop the Cancer Immunotherapy Response CLassifiEr (CIRCLE). Compared to tumor mutational burden alone, CIRCLE led to a superior prediction of ICB response, with a 10.5% increase in sensitivity and an 11% increase in specificity. Such tools may pave the way for better prognostic tools for cancer immunotherapy.
Recurrent somatic mutations as predictors of immunotherapy response
Marcin Imieliński, Neville E. Sanjana
Added on: 10-25-2022
[1] https://www.nature.com/articles/s41467-022-31055-3[2] https://www.drugtargetreview.com/news/104040/whole-exome-sequencing-predicts-whether-cancer-patients-will-respond-to-immunotherapy/?utm_source=Email+marketing&utm_medium=email&utm_campaign=DTR+-+Industry+Insight+-+Bio+IVT+-+Immuno-oncology+-+09.09.22&utm_term=Researchers+develop+a+small+molecule+that+makes+immunotherapy+available+to+all+cancer+patients&utm_content=https%3a%2f%2femails.drugtargetreview.com%2frussellpublishinglz%2f&gator_td=5XClbgWfLEdipSqm%2bx7T6xcOrwZXFd5HHf%2fL%2feRG%2f55t27jmFadcdE86RpuNbRy5HiTrTnDc%2fD6%2fUBkjtGb%2fRFRupVCI4SBO5uCTEIySmIQyxk36imcqtwbZBLfKmo69WMkmwbfNuobHKAk4VVCsAQ98Wlbqh2CZUK7Nn0lp%2fQTvJ0JJ%2f%2foAYGIXUcRKkik3B14olGYMeaFbWAkp7%2bitbYJIjJfNYGPlOnBom042B9KQqd00h4n%2f6U2%2bzQO%2bTHQU
